SCHEMBL22093033

SCHEMBL22093033

Cc1ccccc1NC(=O)NC(=O)c1c(Cl)cc(C(F)(F)F)cc1Cl

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.55
MAPT P10636 2/20 0.55
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
RAB9A P51151 1/20 0.55
GAA P10253 4/20 0.53
POLB P06746 1/20 0.49
ALDH1A1 P00352 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
LMNA P02545 1/20 0.47
ALOX12 P18054 1/20 0.47
AGTR1 P30556 1/20 0.47
KDR P35968 1/20 0.46
NPY5R Q15761 1/20 0.46
KDM4E B2RXH2 1/20 0.46
DDX3X O00571 1/20 0.45
KDM4C Q9H3R0 1/20 0.45
TAS1R3 Q7RTX0 1/20 0.44
TAS1R1 Q7RTX1 1/20 0.44
TAS1R2 Q8TE23 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23734076 0.85 KMT2A (0.48) HTTMAPTMEN1KMT2AGAA
SCHEMBL22093530 0.78 POLB (0.52) HTTMAPTMEN1KMT2ARAB9A
SCHEMBL22093010 0.77 RAB9A (0.57) HTTMAPTMEN1KMT2ARAB9A
SCHEMBL22092999 0.77 POLB (0.48) HTTMAPTMEN1KMT2ARAB9A
SCHEMBL7748786 0.75 TLR7 (0.49) MAPTMEN1KMT2AGAAALDH1A1
SCHEMBL9348722 0.73 MAPT (0.51) HTTMAPTRAB9AGAAPOLB
SCHEMBL9117160 0.73 TLR7 (0.47) MAPTMEN1KMT2AGAAALDH1A1
SCHEMBL22093006 0.73 PYGL (0.60) HTTMAPTMEN1KMT2ARAB9A
SCHEMBL29384137 0.73 POLB (0.52) HTTMAPTMEN1KMT2ARAB9A
SCHEMBL8657066 0.72 MEN1 (0.50) MAPTMEN1KMT2ARAB9AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12503467-B2 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCES, INC. (US) 2025-12-23 US disclosed
CN-119528824-A 2-Oxo quinazoline derivatives as methionine adenosyltransferase 2A inhibitors 伊迪亚生物科学有限公司 2025-02-28 CN disclosed
CN-113166078-B 2-Oxo quinazoline derivatives as methionine adenosyltransferase 2A inhibitors 伊迪亚生物科学有限公司 2024-11-19 CN disclosed
US-20220106276-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS IDEAYA BIOSCIENCES, INC. 2022-04-07 US disclosed
EP-3894396-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS Ideaya Biosciences, Inc. (US) 2021-10-20 EP disclosed
US-11130759-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCE, INC. (US) 2021-09-28 US disclosed
US-11130759-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCE, INC. (US) 2021-09-28 US disclosed
US-11084798-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCES, INC. (US) 2021-08-10 US disclosed
US-11084798-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCES, INC. (US) 2021-08-10 US disclosed
CN-113166078-A 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors 伊迪亚生物科学有限公司 2021-07-23 CN disclosed
US-11046691-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCES, INC. (US) 2021-06-29 US disclosed
US-11046691-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCES, INC. (US) 2021-06-29 US disclosed
WO-2020123395-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS IDEAYA BIOSCIENCES, INC. (US) 2020-06-18 WO disclosed
WO-2020123395-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS IDEAYA BIOSCIENCES, INC. (US) 2020-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11046691-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors MAT2B, MAT2A, MAT1A HTT 4088/4885MAPT 1760/4885MEN1 1381/4885
US-11130759-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors MAT2B, MAT2A, MAT1A HTT 4088/4885MAPT 1760/4885MEN1 1381/4885
US-11084798-B1 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors MAT2B, MAT2A, MAT1A HTT 4088/4885MAPT 1760/4885MEN1 1381/4885
US-20220106276-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS MAT2B, MAT2A, MAT1A HTT 4088/4885MAPT 1760/4885MEN1 1381/4885
US-12503467-B2 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors MAT2B, MAT2A, MAT1A HTT 4088/4885MAPT 1760/4885MEN1 1381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.